<code id='285AE0F29B'></code><style id='285AE0F29B'></style>
    • <acronym id='285AE0F29B'></acronym>
      <center id='285AE0F29B'><center id='285AE0F29B'><tfoot id='285AE0F29B'></tfoot></center><abbr id='285AE0F29B'><dir id='285AE0F29B'><tfoot id='285AE0F29B'></tfoot><noframes id='285AE0F29B'>

    • <optgroup id='285AE0F29B'><strike id='285AE0F29B'><sup id='285AE0F29B'></sup></strike><code id='285AE0F29B'></code></optgroup>
        1. <b id='285AE0F29B'><label id='285AE0F29B'><select id='285AE0F29B'><dt id='285AE0F29B'><span id='285AE0F29B'></span></dt></select></label></b><u id='285AE0F29B'></u>
          <i id='285AE0F29B'><strike id='285AE0F29B'><tt id='285AE0F29B'><pre id='285AE0F29B'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:459
          Matts Take Column Illustration
          Molly Ferguson for STAT

          American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. At the same time, other patients are suffering, and perhaps dying, because the financial burden brought on by the expensive medicines they need is too high.

          Sit with that like a terrible Zen koan: Medicines are both too cheap and too expensive.

          advertisement

          How is that possible? A lot of it goes back to the 1984 Hatch-Waxman Act, which set up the ecosystem that determines the process by which drugs go from being expensive brands to cheap generics in the U.S.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCJapanesedrugmakerNipponShinyakusaidon

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

          AwoodcutshowingtheBishopofMarseilleduringtheGreatPlagueofProvenceHultonArchive/GettyImagesOnMay25,17